WEST Search History

DATE: Friday, October 29, 2004

Hide?			t Count
	DB=US	SPT,EPAB,JPAB,DWPI,TDBD;)R
	L3	\$phthalate adj15 (nanoparticle or nanosphere)	10
	L2	enteric\$ adj15 (nanoparticle or nanosphere)	7
	L1	enteric\$ adj10 (nanoparticle or nanosphere)	7

END OF SEARCH HISTORY

First Hit Fwd Refs

Previous Doc Go to Doc# Next Doc

Generale Collection Print

L1: Entry 1 of 7

File: USPT

Jan 27, 2004

DOCUMENT-IDENTIFIER: US 6682758 B1

TITLE: Water-insoluble drug delivery system

Other Reference Publication (4):

LeRoux et al., "Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice", Journal of Pharmaceutical Sciences (J-Pharm-Sci) 84:1387-1391, Dec. 1995 (3 pages).

Previous Doc

Next Doc

Go to Doc#

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Generate Collection Print

L1: Entry 3 of 7

File: USPT

Jun 24, 1997

DOCUMENT-IDENTIFIER: US 5641745 A

TITLE: Controlled release biodegradable micro- and nanospheres containing cyclosporin

Abstract Text (1):

A controlled release pharmaceutical formulation which comprises cyclosporin entrapped in a biodegradable polymer to form microspheres or nanospheres such that the cyclosporin is substantially in an amorphous state and the biodegradable polymer comprises greater than 12.5% w/w poly(lactide). The biodegradable polymer is suitably poly-D,L-lactide or a blend of poly-D,L-lactide and poly-D,L-lactide-co-glycolide. Additionally, an enteric coating can be applied to the microspheres or nanospheres or to the oral dosage form incorporating the microspheres or nanospheres to protect the formulation while it passes through the stomach. A particularly suitable formulation comprises 50% w/w cyclosporin-loaded 80:20 blend of poly-D,L-lactide-co-glycolide to poly-D,L-lactide micro- and/or nanospheres. This formulation has the combined properties of nearly complete but relatively slow release of cyclosporin within 8 hours and is useful for targeting cyclosporin to the small intestine when administered orally.

Brief Summary Text (20):

The micro- and nanospheres in accordance with the invention are suitably incorporated into oral dosage forms, such as capsules, tablets, powders including powders capable of effervescing upon addition of water, or suspensions. Additionally, an enteric coating can be applied to the microspheres or nanospheres or to the oral dosage form to protect the formulation while is passes through the stomach to further target release of cyclosporin to the small intestine. Alternatively, the micro- and nanospheres in accordance with the invention can be administered parenterally to release greater than 80%, preferably greater than 90%, of the entrapped cyclosporin in a controlled manner over an 8 hour period.

CLAIMS:

- 5. A controlled release pharmaceutical formulation according to claim 1, further comprising an <u>enteric coating on the microspheres</u> or <u>nanospheres</u> to target release of cyclosporin to the small intestine.
- 13. A method according to claim 10, wherein the formulation further comprises an enteric coating on the microspheres or nanospheres to target release of cyclosporin to the small intestine.
- 19. A method according to claim 18, wherein the formulation further comprises an enteric coating on the microspheres or nanospheres to further target release of cyclosporin to the small intestine.

Previous Doc Next Doc Go to Doc#

Hit List

Clear Generate Collection Print FwdiRefs Bkwd Refs

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 6682758 B1

Using default format because multiple data bases are involved.

L1: Entry 1 of 7

File: USPT

Jan 27, 2004

US-PAT-NO: 6682758

DOCUMENT-IDENTIFIER: US 6682758 B1

TITLE: Water-insoluble drug delivery system

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tabibi; S. Esmail Rockville MD Ezennia; Emmanuel I. Baltimore MD Vishnuvajjala; B. Rao Rockville MD

Gupta; Shanker Rockville MD

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 264/4.6

Full Title Citation Front Review Classification Date Reference September State Paris Claims KMC Draw De

☐ 2. Document ID: US 6355270 B1

L1: Entry 2 of 7

File: USPT

Mar 12, 2002

US-PAT-NO: 6355270

DOCUMENT-IDENTIFIER: US 6355270 B1

** See image for Certificate of Correction **

TITLE: Particles for oral delivery of peptides and proteins

DATE-ISSUED: March 12, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ferrari; Mauro Dublin OH
Dehlinger; Peter J. Palo Alto CA

Martin; Francis J. San Francisco CA

Grove; Carl F. Portola Valley CA

Friend; David R. Menlo Park CA

US-CL-CURRENT: 424/489; 424/185.1, 424/450, 424/451, 514/2, 514/21, 530/300, 530/350

Full Title Citation Front Review Classification Date Reference Control Citation Front Review Claims KiMC Draw, De

☐ 3. Document ID: US 5641745 A

L1: Entry 3 of 7

File: USPT

Jun 24, 1997

US-PAT-NO: 5641745

DOCUMENT-IDENTIFIER: US 5641745 A

TITLE: Controlled release biodegradable micro- and nanospheres containing

cyclosporin

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Ramtoola; Zeibun

Dublin

ΙE

US-CL-CURRENT: <u>514/11</u>; <u>514/772.3</u>

Full | Title | Citation | Front | Review | Classification | Date | Reference | Security | Alleghoets | Claims | KWIC | Draw, Dr

4. Document ID: US 5641515 A

L1: Entry 4 of 7

File: USPT

Jun 24, 1997

US-PAT-NO: 5641515

DOCUMENT-IDENTIFIER: US 5641515 A

TITLE: Controlled release biodegradable nanoparticles containing insulin

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Ramtoola; Zeibun

Dublin

ΙE

Full Title Citation Front Review Classification Date Reference Sequences Anadomenta Claims KMC Draw De

☐ 5. Document ID: WO 9631202 A1

L1: Entry 5 of 7

File: EPAB

Oct 10, 1996

PUB-NO: WO009631202A1

DOCUMENT-IDENTIFIER: WO 9631202 A1

TITLE: CONTROLLED RELEASE BIODEGRADABLE MICRO- AND NANOSPHERES CONTAINING

CYCLOSPORIN

PUBN-DATE: October 10, 1996

INVENTOR-INFORMATION:

NAME

COUNTRY

RAMTOOLA, ZEBUNNISSA

INT-CL (IPC): A61 K 31/13; A61 K 9/16; A61 K 9/51

EUR-CL (EPC): A61K009/16; A61K038/13

Full	Title	Citation	Front	Review	Classification	Date	Reference Sequences (1) Chairms KNMC Drawn D

6. Document ID: EP 1311288 A1, US 20010044416 A1, WO 200195935 A1, AU 200131080 A

L1: Entry 6 of 7

File: DWPI

May 21, 2003

DERWENT-ACC-NO: 2002-138610

DERWENT-WEEK: 200334

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Inducing an antigen specific immune response useful in treating Th1-mediated

inflammatory disorders, e.g., (non)-autoimmune diseases or cancer, comprises

administering a Th2-immunostimulatory nucleic acid and an antigen

INVENTOR: DAVIS, H L; MCCLUSKIE, M J

PRIORITY-DATA: 2000US-177461P (January 20, 2000), 2001US-0768012 (January 22, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1311288 A1	May 21, 2003	E	000	A61K039/39
US 20010044416 A1	November 22, 2001		050	A61K048/00
WO 200195935 A1	December 20, 2001	E	000	A61K039/39
AU 200131080 A	December 24, 2001		000	A61K039/39

INT-CL (IPC): A61 K 9/00; A61 K 31/573; A61 K 31/675; A61 K 31/7088; A61 K 38/13; A61 K 38/19; A61 K 38:19; A61 K 39/00; A61 K 39/002; A61 K 39/02; A61 K 39/08; A61 K 39/12; A61 K 39/145; A61 K 39/29; A61 K 39/295; A61 K 39/39; A61 K 39/395; A61 K A61 P 31/00; A61 P 31/00; A61 P 31/00; A61 P 33/00; A61 P 35/00; A61 P 37/00; A61 K 39/00; A61 K 39/00; A61 K 39/00; A61 K 39/00; A61 K 39/00;

5 m 1 Title (C2 m) = 1 = 1	
TOU THE CHAINS FRONT Penience	Place the attack in the Control of t
11501500	Classification Date Reference Sequences Affect ments Claims KMC Draw De

☐ 7. Document ID: ES 2213770 T3, WO 9631231 A1, AU 9652867 A, ZA 9602671 A, US 5641515 A, EP 820300 A1, IE 80468 B, JP 11503148 W, NZ 304976 A, AU 704875 B, EP 820300 B1, DE 69631824 E

L1: Entry 7 of 7

File: DWPI

Sep 1, 2004

DERWENT-ACC-NO: 1996-464765

DERWENT-WEEK: 200458

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Controlled release insulin nano-particle formulations - comprising poly:alkyl-cyano acrylate polymer entrapping complexed insulin, for treating diabetes

INVENTOR: RAMTOOLA, Z

PRIORITY-DATA: 1995IE-0000237 (April 4, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
ES 2213770 T3	September 1, 2004		000	A61K038/28
WO 9631231 A1	October 10, 1996	E	000	A61K038/28
<u>AU 9652867 A</u>	October 23, 1996		000	A61K038/28
ZA 9602671 A	December 31, 1996		018	A61K000/00
US 5641515 A	June 24, 1997		800	A61K009/14
EP 820300 A1	January 28, 1998	E	000	A61K038/28
IE 80468 B	July 29, 1998		000	A61K009/51
JP 11503148 W	March 23, 1999		019	A61K038/28
NZ 304976 A	April 29, 1999		000	A61K038/28
AU 704875 B	May 6, 1999		000	A61K038/28
EP 820300 B1	March 10, 2004	E	000	A61K038/28
DE 69631824 E	April 15, 2004		000	A61K038/28

INT-CL (IPC): A61 K 0/00; A61 K 9/14; A61 K 9/22; A61 K 9/51; A61 K 38/28; A61 K 47/48

Full Title	Citation	Front	Review	Classification	Date	Reference		er er sagni	4. t	e Allan	Claims	KW1C	Drawt De
			,										_
. Clear _	Genera	ite Coll	ection.	. APrint	l lije	wd Refs	34 2	Bkw	d Ref	S and	Gene	rate O	
		ation of a 1. belock!	elickel ik. sinder	noind of hanceling C.							m/t		115
Te	ms									Docur	ments		
ent	eric\$ adj	10 (na	noparti	cle or nanos	sphere	e)						7	

Display Format: - Change Format

Previous Page

Next Page

Go to Doc#